Blis K12 reduces recurrent tonsillitis in children.
Blis Technologies and Stratum Nutrition presented details from new research published in the journal Therapeutics and Clinical Risk Management, demonstrating the efficacy of the oral probiotic BLIS K12 (,Streptococcus salivarius) in preventing pharyngo-tonsillar infections, or recurrent tonsillitis, in children.
For this single-center, interventional-observational, independent study, 130 children with a history of GABHS (group A beta-hemolytic streptococci) infections were evaluated--76 of whom were enrolled in a 90-day program requiring a once-a-day dose of a lozenge with BLIS K12; the remaining 54 children served as the control group receiving no probiotic. Each subject was monitored for the occurrence of GABHS pharyngo-tonsillitis for at least 12 months following their entry into the study.
Results showed that 88% of the treatment group experienced no pharyngotonsillar infections compared to only 22% of the untreated group. Even 9 months after the use of BLIS K12 had been stopped, the development of new pharyngo-tonsillitis infections was significantly lower when compared to the period before treatment. The results from this study are supportive of previous studies conducted on BLIS K12, where prophylactic administration of BLIS K12 to children with a history of recurrent oral streptococcal infection resulted in clinically meaningful reductions in the episodes of both streptococcal and viral infections, along with concomitant reductions in the number of days using an antibiotic and days absent from school.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Suppliers Corner|
|Date:||Apr 1, 2016|
|Previous Article:||Clinical study demonstrates magtein improves cognitive health.|
|Next Article:||Kyowa Hakko USA promotes staff.|